Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IND Promotion Quandary Again Trips Up Burzynski Research Institute

This article was originally published in The Pink Sheet Daily

Executive Summary

The institute has come under scrutiny in the past for how it describes its investigational cancer products, but more mainstream oncology companies have also been cited for jumping the gun with promotional claims for products FDA hasn’t yet approved.

Advertisement

Related Content

Describing An Investigational Drug On Your Website? Don’t Be Definitive About The Data, FDA Says
CEL-SCI Warning Letter Shows Pitfalls Of Website Presentations Of Investigational Drugs
Cancer Drug Website Draws FDA's Ire For Promoting A Product In Clinical Trials
ChemGenex's Phantom Expanded Access Program For Omapro Cited By FDA

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073592

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel